[go: up one dir, main page]

WO2006114703A3 - Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil) - Google Patents

Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil) Download PDF

Info

Publication number
WO2006114703A3
WO2006114703A3 PCT/IB2006/001044 IB2006001044W WO2006114703A3 WO 2006114703 A3 WO2006114703 A3 WO 2006114703A3 IB 2006001044 W IB2006001044 W IB 2006001044W WO 2006114703 A3 WO2006114703 A3 WO 2006114703A3
Authority
WO
WIPO (PCT)
Prior art keywords
period
time
phenylpiperidin
hydroxyphenyl
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001044
Other languages
French (fr)
Other versions
WO2006114703A2 (en
Inventor
Jerry John Weaver
Lorraine Yurkewicz
Keith David Wilner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2006114703A2 publication Critical patent/WO2006114703A2/en
Publication of WO2006114703A3 publication Critical patent/WO2006114703A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention in one aspect is directed to a method for improving the bio-availability of (IS, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-l-yl) -1-propanol traxoprodil or a pharmaceutically acceptable salt thereof in a human, the method comprising administering over a period of time of at least 24 hours (IS, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4- phenylpiperidin-1-yl) -1-propanol or a pharmaceutically acceptable salt thereof to the human, wherein the period of time over which (IS, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-l-yl) -1-propanol or a pharmaceutically acceptable salt thereof is administered is the sum of a first period of time and a second period of time, wherein the rate of administration over the first period of time is greater than the rate of administration over the second period of time, wherein the bio-availability is improved relative to administration at a constant rate that is equal to the rate of administration over the second period of time.
PCT/IB2006/001044 2005-04-25 2006-04-13 Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil) Ceased WO2006114703A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67494705P 2005-04-25 2005-04-25
US60/674,947 2005-04-25

Publications (2)

Publication Number Publication Date
WO2006114703A2 WO2006114703A2 (en) 2006-11-02
WO2006114703A3 true WO2006114703A3 (en) 2007-03-22

Family

ID=36688172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001044 Ceased WO2006114703A2 (en) 2005-04-25 2006-04-13 Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil)

Country Status (1)

Country Link
WO (1) WO2006114703A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186304A2 (en) * 2000-09-06 2002-03-13 Pfizer Products Inc. Pharmaceutical combinations for the treatment of stroke and traumatic brain injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186304A2 (en) * 2000-09-06 2002-03-13 Pfizer Products Inc. Pharmaceutical combinations for the treatment of stroke and traumatic brain injury

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHN A MCCAULEY: "NR2B subtype-selective NMDA receptor antagonists: 2001-2004", EXPERT OPINION, vol. 15, no. 4, 1 April 2005 (2005-04-01), pages 389 - 407, XP002392768, Retrieved from the Internet <URL:http://www.expertopin.com/doi/abs/10.1517/13543776.15.4.389> [retrieved on 20060627] *
JOHN. A. KEMP: "NMDA receptor pathways as drug targests", NATURE NEUROSCIENCE SUPPLEMENT, vol. 5, November 2002 (2002-11-01), pages 1039 - 1042, XP002392767, Retrieved from the Internet <URL:http://www.nature.com/neuro/journal/v5/n11s/pdf/nn936.pdf> [retrieved on 20060727] *
JOHNSON KIM ET AL: "Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. JAN 2003, vol. 31, no. 1, January 2003 (2003-01-01), pages 76 - 87, XP009069857, ISSN: 0090-9556, Retrieved from the Internet <URL:http://dmd.aspetjournals.org/cgi/reprint/31/1/76> [retrieved on 20060627] *
LORRAINE YURKEWICZ, JOURNAL OF NEUROTRAUMA, vol. 22, no. 12, December 2005 (2005-12-01), pages 1428 - 1443, XP002392769, Retrieved from the Internet <URL:http://www.liebertonline.com/doi/pdf/10.1089/neu.2005.22.1428> [retrieved on 20060727] *

Also Published As

Publication number Publication date
WO2006114703A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer&#39;s disease
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA2427227A1 (en) Lactam compound
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
IL176689A0 (en) Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer&#39;s disease
MXPA05007857A (en) Indole-derivative modulators of steroid hormone nuclear receptors.
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2004028521A3 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
SI1965797T1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
WO2001089494A3 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
BRPI0416882A (en) compound, pharmaceutical composition, method of treating a disorder, and use of a compound
EP1938814A4 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
WO2005014032A3 (en) Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
MXPA06003122A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist.
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2005004854A3 (en) Use of betaine for treating arteritis
TW200616644A (en) Medicine for prevention or treatment of diabetes
CA2632207C (en) Use of calcitonin for the treatment of ra
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06727547

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6727547

Country of ref document: EP